NEW YORK, NY / ACCESSWIRE / October 29, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Dropbox, Inc. (NASDAQGS:DBX)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/dropbox-inc-loss-submission-form?prid=4084&wire=1
Lead Plaintiff Deadline: December 3, 2019
Class Period: on behalf of all persons who purchased Dropbox Class A common stock pursuant or traceable to the registration statement issued in connection with the Company's March 23, 2018 initial public offering.
Allegations against DBX include that: (1) Dropbox had materially overstated its ability to monetize its user base; (2) Dropbox was facing worsening revenue trends, which were negatively impacting the Company at the time of the initial public offering ("IPO"); (3) Dropbox was tracking below its internal revenue and monetization targets at the time of the IPO; and (4) as a result, defendants' statements about Dropbox's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Myriad Genetics, Inc. (NASDAQ:MYGN)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/myriad-genetics-inc-loss-submission-form?prid=4084&wire=1
Lead Plaintiff Deadline: November 26, 2019
Class Period: September 2, 2016 to August 13, 2019
Allegations against MYGN include that: (i) Myriad's product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration ("FDA") had requested changes to GeneSight and questioned the validity of the test's purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA's requested changes to GeneSight; (iv) Myriad's acquisition of Counsyl-and thereby, Foresight-caused the Company to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on the Company's revenue; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Domo, Inc. (NASDAQ:DOMO)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/domo-inc-loss-submission-form?prid=4084&wire=1
Lead Plaintiff Deadline: December 16, 2019
Class Period: shareholders who acquired: (a) Domo common stock pursuant and/or traceable to the Company's initial public offering commenced on or around June 29, 2018; or (b) Domo securities between June 28, 2018 and September 5, 2019, both dates inclusive.
Allegations against DOMO include that: (i) Domo was experiencing weakness in its enterprise and international businesses; (ii) Domo's billings growth had dramatically slowed; (iii) all of the foregoing was reasonably likely to have a material negative impact on the Company's financial results; and (iv) as a result, the Offering Documents were materially false and/or misleading and failed to state information required to be stated therein and the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email firstname.lastname@example.org or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com: